Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Docetaxel in Advanced Gastric or GEJ Cancer
NCT00183872Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Apr 2005
- Primary completion
- Oct 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by University of Southern California. Started Apr 2005; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00183872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183872.